Korean J Gastroenterol.  2019 Feb;73(2):70-76. 10.4166/kjg.2019.73.2.70.

Gastroesophageal Reflux Disease

• Park CH
• Lee SK

• KMID: 2438705
• DOI: http://doi.org/10.4166/kjg.2019.73.2.70

Abstract

Gastroesophageal reflux disease (GERD) is a condition that develops when reflux of stomach contents causes troublesome symptoms and/or complications. The prevalence of GERD is increasing worldwide and in Asia-Pacific. The latest Korean guidelines for GERD were published in 2012, and several international guidelines and consensus statements for the management of GERD have also been recently published. Here, we review these guidelines and consensus statements in order to provide a better understanding of the diagnosis and treatment of GERD.

Keyword

Gastroesophageal reflux; Practice guideline

MeSH Terms

Consensus
Diagnosis
Gastroesophageal Reflux*
Gastrointestinal Contents
Prevalence

Figure

• 

  Fig. 1 Algorithm for the evaluation of esophageal symptoms suspected to be the results of reflux etiologies. Adapted from Savarino et al.19, with from Nat Rev Gastroenterol Hepatol. PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease. *If not attempted previously.

Reference

1. Jung H, Hong SJ, Jo YJ, et al. Updated guidelines 2012 for gastroesophageal reflux disease. Korean J Gastroenterol. 2012; 60:195–218.

2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014; 63:871–880.

3. Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016; 65:1402–1415.

4. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther. 2008; 27:173–185.

5. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100:190–200.

6. Hirano I, Richter JE, Practice Parameters. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007; 102:668–685.

7. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008; 135:1383–1391. e1–e5.

8. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008; 23:8–22.

9. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; 108:308–328. quiz 329.

10. Fuchs KH, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc. 2014; 28:1753–1773.

11. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016; 51:751–767.

12. Hunt R, Armstrong D, Katelaris P, et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017; 51:467–478.

13. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the lyon consensus. Gut. 2018; 67:1351–1362.

14. Cho YK, Kim GH, Kim JH, et al. Diagnosis of gastroesophageal reflux disease: a systematic review. Korean J Gastroenterol. 2010; 55:279–295.

15. Lee JH, Cho YK, Jeon SW, et al. Guidelines for the treatment of gastroesophageal reflux disease. Korean J Gastroenterol. 2011; 57:57–66.

16. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. Gastroenterology. 2016; 150:1368–1379.

17. Cho HS, Shin IS, Oh MK, et al. A strategy for dissemination and implementation of clinical practice guidelines in Korea. National Evidence-based Healthcare Collaborating Agency Research Report. 2014; 4:1–213.

18. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900–1920. quiz 1943.

19. Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017; 14:665–676.

20. Farmer AD, Ruffle JK, Aziz Q. The role of esophageal hypersensitivity in functional esophageal disorders. J Clin Gastroenterol. 2017; 51:91–99.

21. Woodland P, Al-Zinaty M, Yazaki E, Sifrim D. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut. 2013; 62:1256–1261.

22. Weijenborg PW, Smout AJ, Verseijden C, et al. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis. Am J Physiol Gastrointest Liver Physiol. 2014; 307:G323–G329.

23. Weijenborg PW, Smout AJ, Bredenoord AJ. Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn. Neurogastroenterol Motil. 2016; 28:1649–1654.

24. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003; 2:132–139.

25. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122:625–632.

26. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013; 11:1585–1591. quiz e90.

27. Manabe N, Haruma K, Ito M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012; 25:373–380.

28. Mendlein J, Sachs G. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase. J Biol Chem. 1990; 265:5030–5036.

29. Kirchhoff P, Andersson K, Socrates T, Sidani S, Kosiek O, Geibel JP. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol. 2006; 291:G838–G843.

30. Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007; 321:866–874.

31. Berg AL, Böttcher G, Andersson K, et al. Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor. Toxicol Pathol. 2008; 36:727–737.

32. Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016; 9:845–852.

33. Han KS, Kim YG, Yoo JK, Lee JW, Lee MG. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm Drug Dispos. 1998; 19:493–500.

34. Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010; 25:1618–1625.

35. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015; 42:1315–1326.

36. Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018; 364:275–286.

37. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016; 43:240–251.

38. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112:1798–1810.